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a b s t r a c t
The aim of the current study is to estimate the epidemiological and economical consequences of several
extended pertussis booster vaccination strategies and to explore the impact of parameters surrounded
by large uncertainty on the cost-effectiveness.
We developed an age structured transmission dynamic model to evaluate the impact of programs
targeting (i) adolescents or adults using a single booster dose, (ii) a combination of adolescent and adult
vaccination, and (iii) an every 10 years booster dose.
The base case analysis, that is a single adolescent booster administered at the age of 12 years, resulted in
a reduction of pertussis infections. However, due to an increase in the number of symptomatic infections
in adults, the beneﬁts in terms of QALYs gained and costs saved in children were partly offset. Despite
thesenegative indirect effects in the adult population, administering an additional booster dose could still
be considered cost effective with an ICER of D 4200 per QALY gained. Combining an adolescent boosterconomics
ooster
ynamic model
dose at the age of 10 (most cost-effective age for a single adolescent booster dose) with an adult (18–30
years) booster dose always resulted in favorable ICERs (<D 10,000/QALY). Finally the every 10year booster
dose resulted in an ICER of D 16,900 per QALY. The impact of different assumptions regarding the disease
epidemiology, disease-related parameters, and vaccination program-related issues was limited.
To conclude,we show that extended pertussis booster vaccination strategies are likely to be considered
as cost-effective.
. Introduction
Pertussis, or whooping cough, is a contagious respiratory tract
isease primarily resulting from infection with Bordetella pertussis.
ertussis continues to be a public health concern even in coun-
ries where a high vaccine coverage for infants and children is
chieved [1]. In the past decade, an increase in the incidence
as been observed in many developed countries combined with
shift in the incidence towards older age groups which may be
elated to increased awareness, changes in disease susceptibil-
ty and vaccine characteristics, shifting demographics, and genetic
ariations [2]. Although pertussis is more severe in infants and
oung children, the increasing incidence in adolescents and adults
s a major concern as adults are an important source of transmis-
ion to infants, and infection in adults causes signiﬁcant morbidity
nd high costs [3–5]. Therefore, extended immunization strategies
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targeting adolescents and adults should be considered. Several
countries, including Australia, Canada, France, and Germany, have
already incorporated adolescent booster doses into their vaccina-
tionprograms [1]. ThecurrentDutchpertussis vaccinationschedule
consists of three primary doses given at 2, 3, and 4months and two
booster doses given at 11 months and at the age of 4 years. An
additional third booster dose could reduce the incidence of per-
tussis in the population [6–8]. However, next to the effectiveness
of such programs, also the economical consequences of such pro-
grams should be taken into account, i.e., can such programs be
considered cost-effective?
Several studies evaluated the cost-effectiveness of extended
pertussis vaccination strategies, but most of them used static
models [9]. However, as pertussis is a transmissible infectious
disease, a dynamic model is required to fully take into account
the transmission of the disease in the population [10]. Up to
now, only two studies have used dynamic models to estimate
the cost-effectiveness of extended pertussis vaccination sched-
ules [7,8]. Although both studies provide plausible insights, they
cannot be used for current decision making in the Netherlands.
Firstly, because the only study that did focus on the Netherlands
was unable to investigate the impact of multiple vaccination sce-
narios and the impact of different assumptions for parameters
surrounded by uncertainty (e.g., duration of protection after nat-
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imes [8]. Secondly, the other study focused speciﬁcally on the USA
ith limited options for transferability to other settings. In par-
icular, whereas various vaccination scenarios were analyzed, no
ransmission related parameters were varied, underreporting for
dultswas not taken into account, and contact rateswere not based
n ‘real life’ contact patterns [7].
Therefore, the aim of the current study is to estimate the cost-
ffectiveness of several extended pertussis booster vaccination
trategies and to explore the impact on the cost-effectiveness of
ifferent assumptions surrounded by uncertainty.
. Methods
In this study we compare the current Dutch pertussis vaccina-
ion programme (with doses provided at 2, 3, 4 and 11months and
years)with different extended vaccination strategies. In the base-
ase (1), representing the scenario in the Netherlands discussed by
heDutchHealth Council, we explored the impact of a third booster
ose provided at the age of 12 years. In addition to this, we also
xplore the following strategies:
. a single (third) booster vaccination with a different timing
(between the ages of 5 and 30);
. a combination of an adolescent booster dose at the age when (1)
is most cost-effective with an adult (18–30 years) booster dose
(fourth booster dose); and
. a booster dose every 10 years starting at the age of 10 until the
age of 60 years.
Our model (programmed in Berkeley Madonna: R. I. Macey & G.
. Oster, UC Berkeley, CA, USA) consists of two parts: a dynamical
ransmission dynamic model used to predict the epidemiological
mpact of the different strategies and an economic analysis, which
s integrated into the transmission model, allowing rapid analy-
es of the economic consequences of epidemiological trends. The
pidemiological model and the economical data are described in
etails in the following section.
.1. Epidemiological model structure
We used an age-structured transmission dynamic model to
redict the impact of the extended pertussis programs as pre-
ented previously [6,8]. Brieﬂy, the model distinguishes between
hree types of infections: (I) primary infections in immunologically
aive individuals; (II) secondary infections in individuals whose
mmune system has been primed by vaccination or infection; and
III) asymptomatic infections (note that all primary and secondary
nfections secondary infections were assumed to be symptomatic).
lso, four typesof immunity are speciﬁed: (1&2) fully immune (i.e.,
mmunity against transmission and disease) by either vaccination
r infection, and (3 & 4) partially immune (i.e., immunity against
isease only) by either vaccination or infection. All epidemiological
ssumptions and parameterswere taken from the base-case analy-
is in Rozenbaumet al. unless stated otherwise [6] and are reported
n Appendix 1.
The model is able to capture effects at the population level,
ncluding herd protection and possible shifts in the average age
f infection.
.2. Economical data and QALYsThe analysis was performed from a societal perspective includ-
ng both direct health care costs and indirect costs of production
osses, updated to 2011 Euroswhen necessary (using the consumer
rice index from The Netherlands’ Central Bureau of Statistics).e 30 (2012) 7327–7331
Direct medical costs included in the analysis were those asso-
ciated with vaccination, diagnostic procedures, hospitalization,
prescribed medicines, prescription fee for the pharmacist, and GP
consultation. Speciﬁc health quality (utility) scores were assigned
to eachhealth state in ourmodel. Assumptions regardingboth costs
and quality of life are more thoroughly discussed in Appendix 2.
2.3. Sensitivity analysis
To test the robustness of the outcomes we performed several
sensitivity analysis on various economical and the epidemiologi-
cal parameters. In the univariate sensitivity analyses, all relevant
parameters were varied by 25% to explore the impact of each
parameter relative to each other.
Based on our previous modeling exercise [6], we decided to
explicitly focus on the duration of protection after a natural infec-
tion and on the underreporting factors as these are extremely
important to drive conclusions about the epidemiology of pertus-
sis after the introduction of an additional booster [6]. Age-speciﬁc
Dutch factors were used to calculate the incidence of unnotiﬁed
cases given that it was estimated that the incidence of pertussis
including (very) mild and asymptomatic cases in the Netherlands
wasmore than 600 times higher than the notiﬁed cases for children
andadults [11].As these ratios are surroundedbyuncertainty, espe-
cially for adolescents and elderly people, the impact of reducing the
underreporting factors by 25% or 50% (i.e., reducing the number
of unnotiﬁed cases) was also investigated. The duration of protec-
tion after natural infection was assumed to be on average 12 years
(fully protected for 2 years and partially protected for 10 years) in
the base case scenario [12], similar to our previous estimate [6]. In
one scenario, we reduced this period to 8 years (fully protected for
2 years and partially protected for 6 years) while in another sce-
nario we increased it up to 16 years (fully protected for 2 years and
partially protected for 14 years). Finally, the impacts of excluding
direct costs, varying the vaccine uptake and the discount rateswere
explored.
2.4. Cost-effectiveness analysis
In the model, a cohort of 185,000 newborns, representing the
Dutch birth cohort was followed twice, once using the current per-
tussis booster programme, and oncewith an extended programme.
In themodel itwas assumed that itwould be possible to implement
a potential booster in 2013. Finally, the time horizon used in the
model was 25 years.
The model tracks the cases of infections, costs, life years (LYs)
and quality-adjusted life years (QALYs). Summing all the costs, LYs
and QALYs and consequently calculating the differences for the
respective outcomes with and without the extended programme
rendered net costs, LYs gained and QALYs gained. Dividing the net
costs by either one of the health effects deﬁned the incremen-
tal cost-effectiveness ratio. Future health effects and the costs of
treatment were discounted according to the Dutch guidelines for
cost-effectiveness research at 1.5% and 4%, respectively [13].
3. Results
3.1. Result base case
The implementation of an adolescent pertussis booster dose
resulted in a reduction of all types of pertussis infections with
the relative decrease being most apparent for primary pertussis
infections. In total 22,400 cases of primary infections, 628,200 of
breakthrough and 2.1million asymptomatic infections could be
avoided (see Table 1). Around 25,200 QALYs could be gained in
M.H. Rozenbaum et al. / Vaccine 30 (2012) 7327–7331 7329
Table 1
Undiscounted base-case analysis results.
Primary infections Recidive infections Asymptomatic cases Cost of vaccination Direct costsa Indirect costs QALYs
Without vaccination 135,938 11,087,800 85,639,500 736,592,000 28,387,100 1,189,260,000 289,116
With vaccination 113,531 10,459,600 83,522,600 844,006,000 26,820,600 1,199,390,000 268,272































Fig. 3. Sensitivity analysis on the base-case cost-effectiveness ratio. The parameters
were varied by 25%. Dark bars show the incremental cost-effectiveness ratio after
a 25% decrease in the parameter (note that it was not possible to increase vaccineig. 1. Age speciﬁc impact of a pertussis booster dose administered at the age of 12
ears on the incremental QALY (dashed line) and total incremental costs (solid line).
orizontal lines show the zero axis for QALYs (dashed line) and costs (solid line).
hildren. However, due to an increase in the number of symp-
omatic infections in adults and elderly as described previously in
ore detail [6], 4400 QALYs would be lost resulting in a net over-
ll number of 20,800 QALYs (see Table 1). Similar to the QALYS,
oth the overall direct and indirect costs would be negative in
dults and elderly (see Fig. 1). This increase in direct costs did
nly partially offset the savings obtained in children. However, due
o indirect costs, productivity losses in adults outweighs the lim-
ted beneﬁts obtained by prevented cases in children (work loss
ue to mothers taking care of their children), there is a net overall
ncrease in productivity losses. The total net costs of an adolescent
ooster program is D 107.4million. Dividing the incremental costs
y the incremental health beneﬁts results in an incremental cost-
ffectiveness ratio of D 5600 per QALY (undiscounted) or D 4200
er QALY when discounted.
.2. Other vaccination strategies
Vaccination at the age of 10 years was the most cost-effective
accination strategy (solid black line in Fig. 2). Increasing the age of
he third booster dose also gradually increased the ICER. Excluding
ndirect costs resulted in a slightly more favorable ICER when the
ig. 2. Impact of age of the third booster dose, discounting and indirect costs on
he incremental cost-effectiveness ratio (ICER) in the base-case analaysis. The solid
ine shows the base-case ICERs (societal perspective combinedwith Dutch discount
ates) while the dashed line shows the ICERs from the health care perspective (ie
nly direct costs). The dotted line shows the ICERs without discounting from the
ocietal while the dashed-dotted line shows the ICERs without discounting from
he health care perspective (ie only direct costs).efﬁcacy), whereas light bars show the incremental cost-effectiveness ratio after a
25% increase. # cases notiﬁedbut not hospitalized;QALY:QualityAdjusted Life Year;
GP: General Practitioner.
third booster was given between the 12 and 14 years of age. How-
ever, if the third booster was provided from 15 years onwards, the
inclusion of indirect costs would result in more favorable ICERs.
Combining a third booster dose at the age of 10 with an adult
(18–30 years) booster dose always resulted in favorable ICERs
(<10,000/QALY). Finally the every 10 year booster dose resulted
in an ICER of D 16,872 per QALY.
3.3. Scenario and sensitivity analyses
Apart from varying the vaccine efﬁcacy of the booster dose, the
QALY losses associatedwith unnotiﬁed pertussis cases and the vac-
cine price, the impact of the other parameterswas very limited (see
Fig. 3). Varying thedurationofprotectionafternatural infectionhad
only a negligible inﬂuence on the ICER when the third booster was
given around the age of 12 (Fig. 4). However, above the age of 15 a
reduction in the duration of natural protection resulted in a more
favorable ICER, while an increase resulted in a less favorable ICER
as compared to the base case. Decreasing the underreporting fac-
tor resulted in more favorable ICERs (Fig. 5). In the base-case the
impact of the vaccine uptake was very limited as the incremental
costs of the booster programme linearly increased with the QALY
gains (data not shown). This was related to the high pressure of
infection which resulted in only minimal herd effects. The impact
of the coverage was much larger when a booster dose was given
Fig. 4. Impact of age and duration of natural protection on the incremental cost-
effectiveness ratio (ICER). The black line shows the ICERs for the base-case analysis
(12 years of protection), the dotted line corresponds to the case of natural duration
of 8 years of protection, and the dashed line corresponds to 16 years of protection.
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iICER). The solid line shows the ICERs for the base-case analysis, the dashed line in
ase the underreporting factor is reduced by 25%, and the dotted line when the
nderreporting factor is reduced by 50%.
very 10 years. Surprisingly, when health and costs were not dis-
ounted the ICER became less favorable, i.e., discounting made the
CERs more favorable.
. Discussion
In this paper, we show that an additional booster dose against
ertussis is likely to be considered as cost-effective by using an age-
tructured deterministic pertussis model integrated with a health
conomical model. Furthermore, by using this model wewere able
o show that the impact of different assumptions, regarding the
isease epidemiology, disease-related parameters, and vaccination
rogram-related issues, does not change the main result: vaccina-
ion is likely to be considered cost-effective.
Only two previous studies estimated the cost-effectiveness of
n additional pertussis booster dose by using a dynamic transmis-
ion model [7,8]. The most recent model was also developed for
he Netherlands, and was used to estimate the cost-effectiveness
f an additional pertussis booster dose at the age of 12 years. It
as a stochastic and individual-based model, while our model is
population-based model. The main advantage of our model is
he running time, which made it possible to explore fully, within
reasonable time, the impact of different assumptions on dis-
aseepidemiology (e.g., underreporting factors), ondisease-related
arameters (e.g., duration of protection after natural immunity),
nd on vaccination program-related issues (e.g., age of the booster
nd vaccine uptake). Moreover, in this paper we used the most
ecent cost data available. Despite these differences both models
howed that an additional booster dose at the age of 12 years can
e labeled as cost-effective, as interventions with an ICER of less
han D 20,000/QALY are considered favorable in the Netherlands
14,15]. The secondstudy [7]usedadynamical compartmentmodel
o estimate the cost effectiveness of pertussis vaccination strate-
ies in the USA. This study showed that implementation of booster
accination could be considered as cost effective or even cost sav-
ng. Unfortunately, this study did not take underreporting cases in
dults into account, which could potentially overestimate the ICER
s we showed in this paper. An advantage of the USA study was
hat it also modeled the impact of cocooning. That is protecting
nfants indirectly by vaccinating their parents. Unfortunately, spe-
iﬁc household contact patterns for parents and infants were not
vailable for the Netherlands whichmade it impossible to consider
uch strategy with our dynamic model. However, previous work
ased on a static model showed that cocooning was likely to be
onsidered as cost-effective [16].
One of the advantages of ourmodel was the possibility to inves-
igate the impactof several scenarios.Weshowed that the impactof
on-disease related parameters such as cost parameters and utility
ecrements had only a very limited impact on the ICER. Also, the
mpact of different disease related parameters was very limited.e 30 (2012) 7327–7331
However, the impact of these of these parameters became more
apparent with an increase of the age of the third booster. Surpris-
ingly, discounting resulted inmore favorable ICERs as compared to
no discounting. This could be explained by the increase in pertus-
sis infections in the older age groups due to a booster dose. More
QALYs are gained andmore direct costs are avertedwhen costs and
QALYs were not discounted. However, a doubling in the productiv-
ity losses in the older age groups (with age the average productivity
losses per individual increase due to both an increase in wages
and working hours) combined with a 50% increase in the incre-
mental programme costs, when the outcome measures were not
discounted,made that discounting the outcomes resulted in amore
favorable ICER. Decreasing the underreporting factors resulted in
more favorable ICERs. The reason being that with a lower under-
reporting rate, the pressure of infection decreased resulting in the
prevention of relatively more symptomatic cases by herd effects in
younger individuals. In addition, the relative increase in thenumber
of symptomatic cases in the older individuals was reduced. Finally,
we note that exclusion of indirect costs resulted in a more favor-
able ICER when the booster was given at 12–14 years of age, but
inclusion of these costs resulted in amore favorable ICERwhen the
booster was provided at 15 years of age. This is directly related to
the fact that when a booster is provided at 15 years productivity
losses are prevented leading to cost saving, while if the vaccine is
provided at the age of 12 years this would result in an increase in
productivity losses and costs. This difference is indirectly caused
by the waning immunity of the vaccine. If a booster dose was
provided at the age of 12 years, the increase in the number of
secondary infection would start at an earlier age than when the
booster was provided at the age of 15 years. Furthermore, with
regard to productivity losses we assumed that individuals start to
have productivity losses at the age of 15 years. As a consequence,
when a booster was given at the age of 15 years, more produc-
tivity losses would be avoided in the “targeted” population. An
assumption of our model structure is that pertussis, or pertussis
immunization, induces immunityagainst transmissionanddisease.
As a consequence vaccinating individuals against pertussis can pre-
vent the transmission of pertussis to other individuals resulting
in herd protection. Although, the exact duration of this immunity
against transmission is not known, there is evidence that vacci-
nations do induce herd protection. For example, in Sweden after
the re-introduction of the pertussis vaccine in 1995 after 16 years,
a signiﬁcant reduction in the number of isolates in unvaccinated
infants was noticed [17]. Also, several other observational stud-
ies [17–19] have demonstrated a decrease in B. pertussis incidence
rates in unvaccinated subgroups (when the vaccination uptakewas
higher than 80%). Furthermore, a decrease in the transmission of B.
pertussis infection fromvaccinated throughhouseholdcontactswas
observed in several vaccine efﬁcacy studies [20–23].
In this analysis we estimated the cost-effectiveness of a pertus-
sis booster vaccine. Given that a single pertussis booster vaccine
is not available, we assumed that the pertussis booster would be
given in the formulation together with diphtheria and tetanus tox-
oids (dTpa vaccine). We explicitly looked at the cost-effectiveness
of apertussisboosterdosewithout taking intoaccount thepotential
effect of the booster dose for diphtheria and tetanus. To fully evalu-
ate the health economic consequences of this combination vaccine,
all three diseases should be taken into account in the model.
We did not consider deaths due to pertussis infections because
in the last decade in theNetherlands on average less than one death
per yearwas reported [24]. Including deathsmight have resulted in
a slightlymore favorable ICER as deaths are assumed to occurmost
frequently in the youngest age groups. On the other hand, if (unre-
ported) deaths occurred more frequently as a result of secondary
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In conclusion, we developed ﬂexible a dynamic model and
howed that a pertussis booster vaccination given at approximately
he age of 12 years is cost-effective given a wide range of assump-
ions. Our results can be used to support decision makers on the
ntroduction of a pertussis booster into the Dutch national immu-
ization programme.
ppendix A. Supplementary data
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/
.vaccine.2012.06.026.
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